Understanding chronic heart failure

Archives of Disease in Childhood

Volumn 92, Issue 9, 2007, Pages 812-816

  Fenton, Matthew ^a   Burch, Michael ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; BUMETANIDE; CAPTOPRIL; COUMARIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; ENOXIMONE; FUROSEMIDE; INOTROPIC AGENT; LOOP DIURETIC AGENT; LOSARTAN; METOLAZONE; PHOSPHODIESTERASE INHIBITOR; PROPRANOLOL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; WARFARIN;

ANTICOAGULANT THERAPY; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; DRUG ABSORPTION; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; EXCITATION CONTRACTION COUPLING; HEART ARRHYTHMIA; HEART FAILURE; HEART TRANSPLANTATION; HEMODYNAMICS; HOSPITALIZATION; HUMAN; INFLAMMATION; INTENSIVE CARE; LOW DRUG DOSE; MORTALITY; MYOCARDIAL DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DIGOXIN; DIURETICS; FEMALE; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; MALE; MYOCARDIAL CONTRACTION; PHOSPHODIESTERASE INHIBITORS; STEM CELL TRANSPLANTATION;

EID: 34548499658     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2005.086397     Document Type: Review

References (18)

1. Katz AM. The hemodynamic defense reaction. In:Heart failure:pathophysiologyr molecular biology and clinical management. Philadelphia: Lippincott Williams & Wilkins, 2000:109-52.
2. Frantz S, Fraccarollo D, Wagner H, et al. Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovasc Res 2003;57(3):749-56.
3. Hardarson HB, NE, Vallejo JG. Inflammatory mediators in heart failure. In: Chang, AC, Towbin J, eds. Heart failure in children and young adults. Philadelphia: Saunders Elsevier, 2006.
4. Price JF, Thomas AK, Grenier M, et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation 2006;114(10):1063-9.
5. Hunt SA, Abraham WT, Marshall HC, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112(12):e154-235.
6. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341(10):709-17.
7. Wambolt RB, Henning SL, English DR, et al. Regression of cardiac hypertrophy normalizes glucose metabolism and left ventricular function during reperfusion. J Mol Cell Cardiol 1997;29(3):939-48.
8. Lewis AB, Chabot M. The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy. Pediatr Cardiol 1993;14(1):9-12.
9. Stern H, Weil J, Genz T, et al. Captopril in children with dilated cardiomyopathy: acute and long-term effects in a prospective study of hemodynamic and hormonal effects. Pediatr Cardiol 1990;11(1):22-8.
10. Kaye DM, Lambert GW, Lefkovits J, et al. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 1994;23(3):570-8.
11. Covit AB, Schaer GL, Sealey JE, et al. Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure. Am J Med 1983;75(3):445-7.
12. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006;27(2):178-86.
13. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94(11):2807-16.
14. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 2002;106(17):2194-9.
15. Blume ED, Canter CE, Spicer R, et al. Prospective single-arm protocol of carvedilol in children with ventricular dysfunction. Pediatr Cardiol 2006;27(3):336-42.
16. Uretsky BF, Jessup M, Konstam AAA, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation 1990;82:774-80.
17. Schachinger V, Erbs S, Elsasser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355(12):1210-21.
18. Fenton MJ, Chubb H, McMahon AM, et al. Heart and heart-lung transplantation for idiopathic restrictive cardiomyopathy in children. Heart 2006;92(1):85-9.